NEW: Premarket Now Starts at 4AM!

We’re excited to announce the extension of premarket and aftermarket hours! Our members now have access to quotes daily from 4:00 AM to 8:00 PM ET — offering greater flexibility and deeper insights into market trends beyond regular trading hours.

Upgrade to FINVIZ*Elite to access premarket quotes »

Last Close
May 23 04:00PM ET
16.40
Dollar change
-0.37
Percentage change
-2.21
%
IndexRUT P/E- EPS (ttm)-1.93 Insider Own34.38% Shs Outstand49.04M Perf Week-2.73%
Market Cap804.74M Forward P/E- EPS next Y-2.76 Insider Trans-0.83% Shs Float32.20M Perf Month-10.38%
Income-94.83M PEG- EPS next Q-0.59 Inst Own73.74% Short Float21.62% Perf Quarter-23.19%
Sales0.00M P/S- EPS this Y-26.71% Inst Trans6.01% Short Ratio22.93 Perf Half Y-37.36%
Book/sh5.88 P/B2.79 EPS next Y-15.19% ROA-29.39% Short Interest6.96M Perf Year-28.38%
Cash/sh5.90 P/C2.78 EPS next 5Y-21.18% ROE-31.30% 52W Range13.30 - 30.03 Perf YTD-27.11%
Dividend Est.- P/FCF- EPS past 5Y19.02% ROI-32.89% 52W High-45.39% Beta0.79
Dividend TTM- Quick Ratio21.06 Sales past 5Y0.00% Gross Margin- 52W Low23.31% ATR (14)1.41
Dividend Ex-Date- Current Ratio21.06 EPS Y/Y TTM-0.19% Oper. Margin- RSI (14)39.06 Volatility2.62% 4.17%
Employees62 Debt/Eq0.00 Sales Y/Y TTM- Profit Margin- Recom1.11 Target Price37.25
Option/ShortYes / Yes LT Debt/Eq0.00 EPS Q/Q-5.45% Payout- Rel Volume0.73 Prev Close16.77
Sales Surprise- EPS Surprise-13.66% Sales Q/Q- EarningsMay 14 AMC Avg Volume303.59K Price16.40
SMA20-11.40% SMA50-12.41% SMA200-27.08% Trades Volume222,508 Change-2.21%
Date Action Analyst Rating Change Price Target Change
Dec-13-24Initiated BTIG Research Buy $42
Sep-09-24Initiated H.C. Wainwright Buy $37
Jun-11-24Initiated Robert W. Baird Outperform $32
Apr-09-24Initiated Mizuho Buy $34
Mar-29-23Initiated Jefferies Buy $27
May-22-25 04:05PM
May-17-25 12:40PM
May-14-25 04:05PM
09:56AM
Apr-22-25 02:54PM
04:03PM Loading…
Apr-02-25 04:03PM
Mar-13-25 04:05PM
Feb-25-25 04:05PM
Jan-31-25 07:00AM
Nov-13-24 04:05PM
Nov-07-24 04:05PM
Oct-18-24 04:38PM
Oct-04-24 09:00AM
Sep-30-24 04:52AM
Sep-28-24 09:35AM
08:50AM Loading…
Sep-26-24 08:50AM
Sep-18-24 04:05PM
Sep-09-24 02:05PM
Sep-04-24 09:55AM
Aug-16-24 09:55AM
Aug-13-24 04:05PM
May-29-24 04:05PM
May-20-24 05:06PM
May-14-24 10:54PM
05:01PM
04:05PM
Apr-19-24 03:03PM
Apr-11-24 03:44PM
07:55AM
Apr-09-24 04:05PM
04:05PM Loading…
Mar-28-24 04:05PM
Mar-23-24 01:51AM
Mar-19-24 08:30AM
Mar-14-24 09:53PM
04:05PM
Feb-27-24 04:05PM
Jan-03-24 09:01AM
Nov-09-23 04:05PM
Aug-17-23 06:40AM
Aug-10-23 04:05PM
May-31-23 04:55PM
May-11-23 04:05PM
Mar-24-23 06:30AM
Enliven Therapeutics, Inc. is a clinical-stage biopharmaceutical company, which focuses on the discovery and development of small molecule therapeutics. Its pipeline includes BCR-ABL Program: ELVN-001and HER2 Program: ELVN-002. The company was founded by Samuel S. Kintz, Joseph P. Lyssikatos, and Anish Patel on June 1, 2019 and is headquartered in Boulder, CO.
Insider Trading Relationship Date Transaction Cost #Shares Value ($) #Shares Total SEC Form 4
Lyssikatos Joseph PCHIEF SCIENTIFIC OFFICERMay 19 '25Sale16.315,00081,534985,188May 21 06:31 PM
Kintz SamuelPRESIDENT AND CEOMay 19 '25Sale16.495,00082,453972,892May 21 06:29 PM
Kintz SamuelOfficerMay 19 '25Proposed Sale16.865,00084,300May 19 04:22 PM
Lyssikatos Joseph POfficerMay 19 '25Proposed Sale16.865,00084,300May 19 04:21 PM
Patel AnishCHIEF OPERATING OFFICERMay 07 '25Sale18.396,667122,579309,976May 09 06:48 PM
Patel AnishOfficerMay 07 '25Proposed Sale19.696,667131,273May 07 04:11 PM
Lyssikatos Joseph PCHIEF SCIENTIFIC OFFICERMay 01 '25Sale20.075,030100,966992,658May 05 06:43 PM
Lyssikatos Joseph PCHIEF SCIENTIFIC OFFICERMay 02 '25Sale20.012,47049,424990,188May 05 06:43 PM
Kintz SamuelPRESIDENT AND CEOMay 01 '25Sale20.085,330107,007980,062May 05 06:42 PM
Kintz SamuelPRESIDENT AND CEOMay 02 '25Sale20.002,17043,409977,892May 05 06:42 PM
Lyssikatos Joseph POfficerMay 01 '25Proposed Sale18.947,500142,050May 01 04:03 PM
Kintz SamuelOfficerMay 01 '25Proposed Sale18.947,500142,050May 01 04:02 PM
Hohl BenjaminCHIEF FINANCIAL OFFICERApr 28 '25Option Exercise2.483,2508,06026,250Apr 30 06:59 PM
Hohl BenjaminCHIEF FINANCIAL OFFICERApr 28 '25Sale18.693,25060,73823,000Apr 30 06:59 PM
Hohl BenjaminOfficerApr 28 '25Proposed Sale18.213,25059,182Apr 28 04:19 PM
Lyssikatos Joseph PCHIEF SCIENTIFIC OFFICERApr 21 '25Sale16.075,00080,366997,688Apr 23 05:09 PM
Kintz SamuelPRESIDENT AND CEOApr 17 '25Sale16.425,00082,096985,392Apr 21 05:55 PM
Lyssikatos Joseph POfficerApr 21 '25Proposed Sale16.535,00082,650Apr 21 04:28 PM
Kintz SamuelOfficerApr 17 '25Proposed Sale16.075,00080,350Apr 17 04:19 PM
Patel AnishMember of immediate family of Apr 14 '25Proposed Sale16.512,01033,185Apr 14 04:54 PM
Patel AnishMember of immediate family of Apr 14 '25Proposed Sale16.512,01033,185Apr 14 04:48 PM
Patel AnishCHIEF OPERATING OFFICERApr 07 '25Sale18.046,667120,269316,643Apr 09 04:25 PM
Patel AnishOfficerApr 07 '25Proposed Sale18.696,667124,606Apr 07 04:09 PM
Hohl BenjaminCHIEF FINANCIAL OFFICERMar 27 '25Option Exercise2.483,2508,06026,250Mar 31 07:37 PM
Hohl BenjaminCHIEF FINANCIAL OFFICERMar 27 '25Sale21.333,25069,32123,000Mar 31 07:37 PM
Hohl BenjaminOfficerMar 27 '25Proposed Sale20.584,25087,465Mar 27 04:01 PM
Hohl BenjaminCHIEF FINANCIAL OFFICERMar 24 '25Option Exercise2.481,0002,48024,000Mar 26 07:37 PM
Hohl BenjaminCHIEF FINANCIAL OFFICERMar 24 '25Sale22.501,00022,50423,000Mar 26 07:37 PM
Lyssikatos Joseph PCHIEF SCIENTIFIC OFFICERMar 19 '25Sale20.6112,500257,5751,002,688Mar 21 05:49 PM
Kintz SamuelPRESIDENT AND CEOMar 17 '25Sale20.8312,500260,320990,392Mar 19 05:42 PM
Lyssikatos Joseph POfficerMar 19 '25Proposed Sale20.2812,500253,500Mar 19 04:18 PM
Kintz SamuelMember of immediate family of Mar 18 '25Proposed Sale21.0421,531453,012Mar 18 04:14 PM
Kintz SamuelMember of immediate family of Mar 18 '25Proposed Sale21.0421,531453,012Mar 18 04:06 PM
Kintz SamuelOfficerMar 17 '25Proposed Sale20.7412,500259,250Mar 17 04:14 PM
Patel AnishMember of immediate family of Mar 17 '25Proposed Sale20.742,50051,850Mar 17 04:08 PM
Patel AnishMember of immediate family of Mar 17 '25Proposed Sale20.742,50051,850Mar 17 04:04 PM
Patel AnishCHIEF OPERATING OFFICERMar 07 '25Sale21.446,667142,936323,310Mar 11 05:18 PM
Patel AnishOfficerMar 07 '25Proposed Sale21.466,667143,074Mar 07 04:18 PM
Hohl BenjaminCHIEF FINANCIAL OFFICERMar 04 '25Option Exercise2.4810,00024,80023,000Mar 06 06:02 PM
Hohl BenjaminCHIEF FINANCIAL OFFICERFeb 27 '25Option Exercise2.483,2508,06016,250Mar 03 08:07 PM
Hohl BenjaminCHIEF FINANCIAL OFFICERFeb 27 '25Sale20.413,25066,32713,000Mar 03 08:07 PM
Hohl BenjaminOfficerFeb 27 '25Proposed Sale20.284,25086,190Feb 27 04:10 PM
Patel AnishMember of immediate family of Feb 14 '25Proposed Sale21.502,50053,750Feb 14 05:02 PM
Patel AnishMember of immediate family of Feb 14 '25Proposed Sale21.502,50053,750Feb 14 04:17 PM
Patel AnishCHIEF OPERATING OFFICERFeb 07 '25Sale21.936,667146,206329,977Feb 10 05:32 PM
Hohl BenjaminCHIEF FINANCIAL OFFICERFeb 05 '25Option Exercise2.481,0002,48014,000Feb 07 07:06 PM
Hohl BenjaminCHIEF FINANCIAL OFFICERFeb 05 '25Sale22.521,00022,52413,000Feb 07 07:06 PM
Patel AnishOfficerFeb 07 '25Proposed Sale22.476,667149,807Feb 07 04:02 PM
Hohl BenjaminCHIEF FINANCIAL OFFICERJan 27 '25Option Exercise2.483,2508,06016,250Jan 29 07:21 PM
Hohl BenjaminCHIEF FINANCIAL OFFICERJan 27 '25Sale21.593,25070,17813,000Jan 29 07:21 PM
Hohl BenjaminOfficerJan 27 '25Proposed Sale21.864,25092,905Jan 27 04:37 PM
Patel AnishMember of immediate family of Jan 14 '25Proposed Sale22.072,50055,175Jan 14 04:06 PM
Patel AnishMember of immediate family of Jan 14 '25Proposed Sale22.072,50055,175Jan 14 04:01 PM
Patel AnishCHIEF OPERATING OFFICERJan 07 '25Option Exercise1.8121,70039,26421,700Jan 10 05:31 PM
Patel AnishCHIEF OPERATING OFFICERJan 07 '25Sale24.1821,700524,6970Jan 10 05:31 PM
Patel AnishCHIEF OPERATING OFFICERJan 07 '25Sale24.176,667161,171336,644Jan 10 05:31 PM
Hohl BenjaminCHIEF FINANCIAL OFFICERDec 13 '24Option Exercise2.4813,00032,24013,000Jan 07 04:43 PM
Hohl BenjaminCHIEF FINANCIAL OFFICERJan 03 '25Option Exercise2.481,0002,48014,000Jan 07 04:43 PM
Hohl BenjaminCHIEF FINANCIAL OFFICERJan 03 '25Sale25.041,00025,03913,000Jan 07 04:43 PM
Patel AnishOfficerJan 07 '25Proposed Sale24.0728,367682,794Jan 07 04:21 PM
Hohl BenjaminOfficerJan 03 '25Proposed Sale23.901,00023,900Jan 03 04:05 PM
Hohl BenjaminCHIEF FINANCIAL OFFICERDec 27 '24Option Exercise2.483,3508,3083,350Dec 31 05:18 PM
Hohl BenjaminCHIEF FINANCIAL OFFICERDec 30 '24Option Exercise2.489002,232900Dec 31 05:18 PM
Hohl BenjaminCHIEF FINANCIAL OFFICERDec 27 '24Sale22.153,35074,2190Dec 31 05:18 PM
Hohl BenjaminCHIEF FINANCIAL OFFICERDec 30 '24Sale22.5190020,2550Dec 31 05:18 PM
Hohl BenjaminOfficerDec 27 '24Proposed Sale22.714,25096,518Dec 27 04:33 PM
Patel AnishMember of immediate family of Dec 16 '24Proposed Sale23.152,50057,875Dec 16 04:30 PM
Patel AnishMember of immediate family of Dec 16 '24Proposed Sale23.152,50057,875Dec 16 04:15 PM
Hohl BenjaminCHIEF FINANCIAL OFFICERNov 27 '24Option Exercise2.485,25013,0205,250Dec 02 05:18 PM
Hohl BenjaminCHIEF FINANCIAL OFFICERNov 27 '24Sale24.895,250130,6880Dec 02 05:18 PM
Patel AnishMember of immediate family of Nov 15 '24Proposed Sale24.9217,500436,100Nov 15 04:35 PM
Patel AnishMember of immediate family of Nov 15 '24Proposed Sale24.9217,500436,100Nov 15 04:28 PM
Hohl BenjaminCHIEF FINANCIAL OFFICEROct 28 '24Option Exercise2.486,25015,5006,250Oct 30 06:04 PM
Hohl BenjaminCHIEF FINANCIAL OFFICEROct 28 '24Sale28.566,250178,4850Oct 30 06:04 PM
Patel AnishCHIEF OPERATING OFFICEROct 18 '24Sale30.0071621,483343,311Oct 22 04:23 PM
Lyssikatos Joseph PCHIEF SCIENTIFIC OFFICEROct 18 '24Sale30.0084725,4131,015,188Oct 22 04:22 PM
Kintz SamuelPRESIDENT AND CEOOct 18 '24Sale30.0092427,7231,002,892Oct 22 04:21 PM
Hohl BenjaminCHIEF FINANCIAL OFFICEROct 18 '24Option Exercise2.488142,019814Oct 22 04:19 PM
Hohl BenjaminCHIEF FINANCIAL OFFICEROct 18 '24Sale30.0081424,4220Oct 22 04:19 PM
Heyman Richard A.DirectorOct 18 '24Sale30.0081724,512123,673Oct 22 04:18 PM
Heyman Richard A.DirectorOct 18 '24Sale30.0075322,59227,165Oct 22 04:18 PM
Collins Helen LouiseCHIEF MEDICAL OFFICEROct 18 '24Option Exercise2.488162,024816Oct 22 04:17 PM
Collins Helen LouiseCHIEF MEDICAL OFFICEROct 18 '24Sale30.0081624,4820Oct 22 04:17 PM
Patel AnishOfficerOct 18 '24Proposed Sale28.0250,0001,401,000Oct 18 06:42 PM
Lyssikatos Joseph POfficerOct 18 '24Proposed Sale28.0265,0001,821,300Oct 18 05:42 PM
Heyman Richard A.DirectorOct 18 '24Proposed Sale28.021,56643,879Oct 18 05:27 PM
Kintz SamuelOfficerOct 18 '24Proposed Sale28.0291,1232,553,266Oct 18 05:17 PM
Heyman Richard A.DirectorOct 18 '24Proposed Sale28.0212,165340,863Oct 18 05:10 PM
Hohl BenjaminOfficerOct 18 '24Proposed Sale28.0213,000364,260Oct 18 05:00 PM
Collins Helen LouiseOfficerOct 18 '24Proposed Sale28.0225,000700,500Oct 18 04:57 PM
Heyman Richard A.DirectorOct 15 '24Sale27.671,27035,143124,490Oct 17 05:06 PM
Heyman Richard A.DirectorOct 15 '24Proposed Sale27.751,27035,242Oct 15 04:38 PM
Lyssikatos Joseph PCHIEF SCIENTIFIC OFFICEROct 09 '24Sale28.1637,8781,066,5611,016,035Oct 10 08:39 PM
Lyssikatos Joseph PCHIEF SCIENTIFIC OFFICEROct 08 '24Sale27.9713,267371,0241,053,913Oct 10 08:39 PM
Kintz SamuelPRESIDENT AND CEOOct 09 '24Sale28.1516,710470,4051,003,816Oct 10 08:38 PM
Kintz SamuelPRESIDENT AND CEOOct 08 '24Sale27.9613,267370,9291,020,526Oct 10 08:38 PM
Ballal Rahul D.DirectorOct 08 '24Option Exercise14.1010,420146,92532,761Oct 10 08:36 PM
Ballal Rahul D.DirectorOct 08 '24Sale28.1710,420293,55722,341Oct 10 08:36 PM
Lyssikatos Joseph POfficerOct 09 '24Proposed Sale28.0112,000336,120Oct 09 04:27 PM
Kintz SamuelOfficerOct 09 '24Proposed Sale28.0112,000336,120Oct 09 04:16 PM
Last Close
May 23 04:00PM ET
0.3329
Dollar change
-0.0065
Percentage change
-1.92
%
TSBX Turnstone Biologics Corp daily Stock Chart
Index- P/E- EPS (ttm)-2.73 Insider Own25.54% Shs Outstand23.14M Perf Week-0.69%
Market Cap7.70M Forward P/E- EPS next Y-0.51 Insider Trans0.00% Shs Float17.23M Perf Month4.36%
Income-63.01M PEG- EPS next Q-0.16 Inst Own22.77% Short Float2.03% Perf Quarter-19.73%
Sales0.00M P/S- EPS this Y77.52% Inst Trans11.20% Short Ratio3.13 Perf Half Y-29.32%
Book/sh0.86 P/B0.39 EPS next Y26.09% ROA-103.30% Short Interest0.35M Perf Year-88.15%
Cash/sh0.95 P/C0.35 EPS next 5Y- ROE-126.03% 52W Range0.29 - 3.05 Perf YTD-33.00%
Dividend Est.- P/FCF- EPS past 5Y- ROI-315.29% 52W High-89.09% Beta1.27
Dividend TTM- Quick Ratio3.70 Sales past 5Y-67.10% Gross Margin- 52W Low14.79% ATR (14)0.03
Dividend Ex-Date- Current Ratio3.70 EPS Y/Y TTM16.34% Oper. Margin- RSI (14)44.39 Volatility2.26% 3.42%
Employees14 Debt/Eq0.03 Sales Y/Y TTM-100.00% Profit Margin- Recom3.00 Target Price1.00
Option/ShortNo / Yes LT Debt/Eq0.00 EPS Q/Q40.19% Payout- Rel Volume0.10 Prev Close0.34
Sales Surprise- EPS Surprise-96.15% Sales Q/Q- EarningsMay 08 AMC Avg Volume111.66K Price0.33
SMA20-3.02% SMA50-8.22% SMA200-37.01% Trades Volume10,845 Change-1.92%
Date Action Analyst Rating Change Price Target Change
Feb-05-25Downgrade Piper Sandler Overweight → Neutral $3.75 → $0.40
Nov-15-24Downgrade BofA Securities Neutral → Underperform
Oct-14-24Downgrade BofA Securities Buy → Neutral
Aug-16-23Initiated SVB Securities Market Perform
Aug-15-23Initiated Piper Sandler Overweight $20
Aug-15-23Initiated BofA Securities Buy $18
May-08-25 06:00PM
Mar-28-25 09:03PM
Feb-07-25 12:00PM
Feb-05-25 06:28AM
Feb-04-25 09:00AM
04:05PM Loading…
Nov-12-24 04:05PM
Nov-05-24 09:01AM
Oct-12-24 06:47AM
Oct-11-24 06:36AM
06:00AM
Aug-14-24 09:54PM
04:05PM
04:01PM
Aug-12-24 05:49PM
May-13-24 09:53PM
05:01PM Loading…
05:01PM
May-08-24 09:00AM
Apr-16-24 09:00AM
Mar-22-24 07:52AM
Mar-21-24 05:06PM
Feb-21-24 06:00AM
Feb-20-24 05:00PM
Nov-27-23 06:00AM
Nov-09-23 09:49PM
Nov-03-23 06:00AM
Oct-30-23 06:00AM
Sep-28-23 06:00AM
Sep-01-23 05:57PM
Aug-14-23 08:41PM
Aug-04-23 06:30PM
07:01PM Loading…
Jul-27-23 07:01PM
05:36PM
Jul-21-23 02:15AM
Turnstone Biologics Corp. operates as a clinical stage biotechnology company. It engages in the business of developing and commercializing therapeutics. The company is focused on developing new medicines to treat and cure patients with solid tumors. Turnstone Biologics was founded in 2015 and is headquartered in La Jolla, CA.